Targeted Medical Pharma Forms Distribution Partnership with Cannabinoid Genetic Research Firm, ENDOCANNA Health

Los Angeles, February 6,  2019 – Targeted Medical Pharma (OTC: TRGM), today announced the completion of a distribution agreement with ENDOCANNA Health, a company that specializes in  personalized cannabis through a comprehensive Cannabinoid DNA Variant Test™.  

The Agreement is the first step in a multiyear partnership to improve personalized medicine by connecting clinical nutrition and the DNA variants that influence the endocannabinoid system to create effective and safer therapies for the long term management of chronic disease.  

Under the terms of the Agreement, ENDOCANNA Health has a three year nonexclusive right to the domestic distribution of the Company’s line of patented medical food products to include in their DNA Variant Testing program which is currently offered Nationwide by physicians and retailers.

“This partnership provides new opportunities for the research and development of novel therapies and clinical protocols capable of improving cannabinoid therapies for people suffering with chronic pain, anxiety, sleep disorders and obesity,” said Marcus Charuvastra, Managing Director of Targeted Medical Pharma. “Medical foods and phytocannabinoid therapies when used appropriately can have a very positive impact on nervous and endocannabinoid system health, restoring balance to systems that are degraded by disease, toxins, stress and genetics.”   

“Our partnership provides a unique opportunity to offer adjunct therapies that target multiple endogenous pathways simultaneously,” said Len May, CEO and co-founder of Endocanna Health. “By using Endocanna Health’s proprietary DNA report, we provide genetically-aligned protocols for clinicians to offer their patients along with analytical tools for clinical trials.” 

Connect with us on Twitter and Facebook.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops medical foods for the dietary management of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness. 

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

####

Targeted Medical Pharma Files SEC Form 15

Los Angeles – October 19, 2018 –  Targeted Medical Pharma a United States based medical nutrition and dietary supplement manufacturer, filed a Form 15 with the Securities and Exchange Commission. “After a detailed analysis and thoughtful deliberation of the advantages and disadvantages of being an SEC reporting company, the company’s board of directors and management concluded that the costs of reporting are too high and unreasonably burdensome on a company that is restructuring and rebuilding,” said interim Managing Director, Marcus Charuvastra. 

According to Mr. Charuvastra, “The preparation and filing of reports, retention of outside legal and accounting resources, in addition to the amount of management time spent on the documents along with the current volume of trading common stock do not justify being a SEC reporting company.” 

The Company will continue to file reports as required for trading common stock on the Pink Sheets. Questions regarding the company and common stock can be directed to info@tmedpharma.com.    

Connect with us on Twitter and Facebook.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. (TRGM) a publicly traded, United States based medical nutrition company that develops amino acid based medical foods and other oral nutrition products for the long term management of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep, respiratory disorders, allergies and cognitive disorders.

The Company manufactures 8 proprietary amino acid based medical foods along with the dietary supplements Grotrexa (Japan), AppTrim (Japan), Hypertensa Advanced and Clearwayz. Each product uses Targeted Cellular Technology, the Company’s patented micro-nutrient delivery system that improves the absorption and cellular utilization of amino acids, nutrients and neurotransmitters. The products are manufactured in the United States and sold directly to physicians, pharmacies and patients in the United States, Japan, New Zealand, Ukraine, Russia and China.

Forward Looking Statement 

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

####